124 related articles for article (PubMed ID: 24633893)
21. Polypoid or non-polypoid? A novel dichotomous approach to uterine carcinosarcoma.
Djordjevic B; Gien LT; Covens A; Malpica A; Khalifa MA
Gynecol Oncol; 2009 Oct; 115(1):32-36. PubMed ID: 19640575
[TBL] [Abstract][Full Text] [Related]
22. Impact of treatment strategies on local control and survival in uterine carcinosarcomas in Turkey.
Kucukoztas N; Dizdar O; Rahatli S; Dursun P; Yalcin S; Altundağ Ö; Ozen O; Reyhan NH; Tarhan C; Yildiz F; Ayhan A
Asian Pac J Cancer Prev; 2013; 14(5):2959-62. PubMed ID: 23803061
[TBL] [Abstract][Full Text] [Related]
23. FIGO staging for carcinosarcoma: can the revised staging system predict overall survival?
Pradhan TS; Stevens EE; Ablavsky M; Salame G; Lee YC; Abulafia O
Gynecol Oncol; 2011 Nov; 123(2):221-4. PubMed ID: 21889193
[TBL] [Abstract][Full Text] [Related]
24. Carcinosarcoma of the uterus: a 40-year experience from the state of Missouri.
Doss LL; Llorens AS; Henriquez EM
Gynecol Oncol; 1984 May; 18(1):43-53. PubMed ID: 6714806
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
Int J Clin Oncol; 2016 Feb; 21(1):168-76. PubMed ID: 26084780
[TBL] [Abstract][Full Text] [Related]
26. Early-stage carcinosarcoma of the uterus: the significance of lymph node count.
Temkin SM; Hellmann M; Lee YC; Abulafia O
Int J Gynecol Cancer; 2007; 17(1):215-9. PubMed ID: 17291256
[TBL] [Abstract][Full Text] [Related]
27. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma.
Cantrell LA; Havrilesky L; Moore DT; O'Malley D; Liotta M; Secord AA; Nagel CI; Cohn DE; Fader AN; Wallace AH; Rose P; Gehrig PA
Gynecol Oncol; 2012 Oct; 127(1):22-6. PubMed ID: 22727985
[TBL] [Abstract][Full Text] [Related]
28. The Effect of Adjuvant Pelvic Radiotherapy on Distant Metastasis for Uterine Carcinosarcoma.
Eng NL; Rana SR; Hall KL; Eng TY
Am J Clin Oncol; 2021 Apr; 44(4):169-173. PubMed ID: 33481373
[TBL] [Abstract][Full Text] [Related]
29. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Wolfson AH; Brady MF; Rocereto T; Mannel RS; Lee YC; Futoran RJ; Cohn DE; Ioffe OB
Gynecol Oncol; 2007 Nov; 107(2):177-85. PubMed ID: 17822748
[TBL] [Abstract][Full Text] [Related]
30. Prognostic determinants in patients with uterine and ovarian carcinosarcoma.
Rauh-Hain JA; Shoni M; Schorge JO; Goodman A; Horowitz NS; del Carmen MG
J Reprod Med; 2013; 58(7-8):297-304. PubMed ID: 23947079
[TBL] [Abstract][Full Text] [Related]
31. Stage III uterine carcinosarcoma: 2009 International Federation of Gynecology and Obstetrics Staging System and Prognostic Determinants.
Garg G; Kruger M; Christensen C; Deppe G; Toy EP
Int J Gynecol Cancer; 2011 Dec; 21(9):1606-12. PubMed ID: 21720252
[TBL] [Abstract][Full Text] [Related]
32. Impact of adjuvant pelvic radiotherapy in stage I uterine sarcoma.
Magnuson WJ; Petereit DG; Anderson BM; Geye HM; Bradley KA
Anticancer Res; 2015 Jan; 35(1):365-70. PubMed ID: 25550573
[TBL] [Abstract][Full Text] [Related]
33. Prognostic features of surgical stage I uterine carcinosarcoma.
Ferguson SE; Tornos C; Hummer A; Barakat RR; Soslow RA
Am J Surg Pathol; 2007 Nov; 31(11):1653-61. PubMed ID: 18059221
[TBL] [Abstract][Full Text] [Related]
34. Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome.
Callister M; Ramondetta LM; Jhingran A; Burke TW; Eifel PJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):786-96. PubMed ID: 14967435
[TBL] [Abstract][Full Text] [Related]
35. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior.
Bansal N; Herzog TJ; Seshan VE; Schiff PB; Burke WM; Cohen CJ; Wright JD
Obstet Gynecol; 2008 Jul; 112(1):64-70. PubMed ID: 18591309
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma.
Şükür YE; Taşkın S; Varlı B; Ateş C; Güngör M; Ortaç F
Int J Clin Oncol; 2018 Feb; 23(1):114-120. PubMed ID: 28836024
[TBL] [Abstract][Full Text] [Related]
37. Survival after pelvic exenteration for uterine malignancy: A National Cancer Data Base study.
Seagle BL; Dayno M; Strohl AE; Graves S; Nieves-Neira W; Shahabi S
Gynecol Oncol; 2016 Dec; 143(3):472-478. PubMed ID: 27760707
[TBL] [Abstract][Full Text] [Related]
38. The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma.
Clayton Smith D; Kenneth Macdonald O; Gaffney DK
Radiother Oncol; 2008 Aug; 88(2):227-32. PubMed ID: 18160157
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes of uterine carcinosarcoma: results of 94 patients.
Gokce ZK; Turan T; Karalok A; Tasci T; Ureyen I; Ozkaya E; Kose MF; Tulunay G
Int J Gynecol Cancer; 2015 Feb; 25(2):279-87. PubMed ID: 25611900
[TBL] [Abstract][Full Text] [Related]
40. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
